Reference entry — not sold here. The oral, non-peptide sibling of the injectable GHRPs: same ghrelin-receptor mechanism, but a pill. Included because the demand is enormous and it sits right next to the GH-peptide cluster — honestly tagged as not a peptide. No dosing published here.
MK-677 (ibutamoren) is an oral, non-peptide ghrelin-receptor agonist — the pill version of the injectable GHRPs. Across ~30 years of trials it reliably raises GH and IGF-1 and deepens slow-wave sleep, and it modestly increases lean mass — but without improving strength or physical function, and at a real metabolic cost (insulin resistance / elevated blood glucose). It's not FDA-approved (the FDA is recalling consumer products that contain it), it carries a congestive-heart-failure safety signal from an elderly trial, and it's banned in sport. It is not a peptide and not a SARM.
not approved.
Not FDA-approved for any indication (30 years on, still unapproved; Merck shelved it, and Lumos's LUM-201 is in pediatric development, not approved). The FDA is actively enforcing against unapproved consumer products — a consumer alert on "iKids-Growth" (Sept 2025) and a recall of "Agebox" products containing undeclared ibutamoren (March 2026). It is not a scheduled substance, but selling it in supplements is unlawful.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026.
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.